Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
StandardStandard
Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective? / Hughes, D.; Hughes, D.A.
2003. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea, Wales, UK.
2003. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea, Wales, UK.
Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
HarvardHarvard
Hughes, D & Hughes, DA 2003, 'Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?', Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea, Wales, UK, 3/01/01.
APA
Hughes, D., & Hughes, D. A. (2003). Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea, Wales, UK.
CBE
Hughes D, Hughes DA. 2003. Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea, Wales, UK.
MLA
Hughes, D. a D.A. Hughes Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?. Welsh Health Economics Group, Swansea, Wales, UK, 03 Ion 0001, Papur, 2003.
VancouverVancouver
Hughes D, Hughes DA. Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?. 2003. Papur a gyflwynwyd yn Welsh Health Economics Group, Swansea, Wales, UK.
Author
RIS
TY - CONF
T1 - Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?
AU - Hughes, D.
AU - Hughes, D.A.
PY - 2003/5/1
Y1 - 2003/5/1
M3 - Paper
T2 - Welsh Health Economics Group, Swansea, Wales, UK
Y2 - 3 January 0001
ER -